ReviewArteriosclerosis, thrombosis, and vascular biology2024
Colchicine's Role in Cardiovascular Disease Management.
Review in Arteriosclerosis, thrombosis, and vascular biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- A pairwise and network meta-analysis of anti-inflammatory strategies after myocardial infarction: the TITIAN study.European heart journal. Cardiovascular pharmacotherapy · 2025Pooled it
- Colchicine for the primary prevention of cardiovascular events.The Cochrane database of systematic reviews · 2025Pooled it
- Efficacy and Safety of Long-term Administration of Various Doses of Colchicine in Patients with Gout.Doklady. Biochemistry and biophysics · 2026Trial
- Where is the plaque signal? Colchicine and coronary atherosclerosis by CCTA.The international journal of cardiovascular imaging · 2026Article
- Article
- Repurposing of colchicine: critical examination of clinical trials and scoping review.European journal of clinical pharmacology · 2026Article
- Colchicine Protects Against Sickle Cell Related Cardiomyopathy: Evidence of the Novel Role of Inflammaging.Antioxidants (Basel, Switzerland) · 2026Article
- Colchicine in Coronary Artery Disease-Too Much of a Good Thing?Journal of cardiovascular development and disease · 2026Review
- Colchicine therapy in transcatheter aortic valve replacement: Modulating inflammation and outcomes.International journal of cardiology. Cardiovascular risk and prevention · 2026Review
- Pharmacological Modulation of Injury-Induced Vascular Remodeling by Colchicine: An Integrated Experimental and Network-Based Analysis.Biomedicines · 2026Article
- Review
- Problems associated with the ATC system of drug classification.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Inflammation-modulating agents in chronic limb-threatening ischemia: a narrative review of therapeutic potential and future directions.Annals of medicine and surgery (2012) · 2026Article
- Delivery of TCM Monomers Using Blood Cell Membrane Coated Biomimetic Nanoparticles to Target CVD.International journal of nanomedicine · 2026Review
- Emerging insights into inflammation-driven atherosclerosis: immune cell mechanisms.Frontiers in cardiovascular medicine · 2026Review
- Research progress on targeted regulatory proteins in the prevention and treatment of atherosclerosis.Frontiers in immunology · 2026Review
- Gut-heart axis disruption and LPS translocation: driving atrial fibrillation through inflammatory storm and fibrotic mechanisms.Frontiers in endocrinology · 2026Review
- Inflammatory Mechanisms in Acute Coronary Syndromes: From Pathophysiology to Therapeutic Targets.Cells · 2025Review
- Colchicine and cardiovascular outcomes in MINOCA: A retrospective cohort study.American heart journal plus : cardiology research and practice · 2025Article
- Colchicine in coronary artery and cerebrovascular disease: "Old skin for the new ceremony".World journal of cardiology · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Colchicine-an anti-inflammatory alkaloid-has assumed an important role in the management of cardiovascular inflammation ≈3500 years after its first medicinal use in ancient Egypt. Primarily used in high doses for the treatment of acute gout flares during the 20th century, research in the early 21st century demonstrated that low-dose colchicine effectively treats acute gout attacks, lowers the risk of recurrent pericarditis, and can add to secondary prevention of major adverse cardiovascular events. As the first Food and Drug Administration-approved targeted anti-inflammatory cardiovascular therapy, colchicine currently has a unique role in the management of atherosclerotic cardiovascular disease. The safe use of colchicine requires careful monitoring for drug-drug interactions, changes in kidney and liver function, and counseling regarding gastrointestinal upset. Future research should elucidate the mechanisms of anti-inflammatory effects of colchicine relevant to atherosclerosis, the potential role of colchicine in primary prevention, in other cardiometabolic conditions, colchicine's safety in cardiovascular patients, and opportunities for individualizing colchicine therapy using clinical and molecular diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.